评估针对阻塞性睡眠呼吸暂停患者白天过度嗜睡的药物治疗:综合网络荟萃分析和系统综述

IF 11.2 1区 医学 Q1 CLINICAL NEUROLOGY Sleep Medicine Reviews Pub Date : 2024-04-30 DOI:10.1016/j.smrv.2024.101934
Seyed Sina Neshat , Afshin Heidari , Mario Henriquez-Beltran , Kripa Patel , Brendon Colaco , Vichaya Arunthari , Alejandra Yu Lee Mateus , Joseph Cheung , Gonzalo Labarca
{"title":"评估针对阻塞性睡眠呼吸暂停患者白天过度嗜睡的药物治疗:综合网络荟萃分析和系统综述","authors":"Seyed Sina Neshat ,&nbsp;Afshin Heidari ,&nbsp;Mario Henriquez-Beltran ,&nbsp;Kripa Patel ,&nbsp;Brendon Colaco ,&nbsp;Vichaya Arunthari ,&nbsp;Alejandra Yu Lee Mateus ,&nbsp;Joseph Cheung ,&nbsp;Gonzalo Labarca","doi":"10.1016/j.smrv.2024.101934","DOIUrl":null,"url":null,"abstract":"<div><p>Obstructive sleep apnea (OSA) is associated with excessive daytime sleepiness (EDS). Pharmacotherapy offers a potential treatment approach for EDS in OSA patients. This systematic review and meta-analysis aimed to assess the efficacy and safety of pharmacological interventions for alleviating EDS in patients with OSA. Following PRISMA guidelines, we included randomized controlled trials investigating pharmacological treatments for EDS in adult OSA until August 2023. We conducted meta-analysis, subgroup, and meta-regression analyses using a random effects model. Finally, a network meta-analysis synthesized direct and indirect evidence, followed by a comprehensive safety analysis. We included 32 articles in the meta-analysis (n = 3357). Pharmacotherapy showed a significant improvement in the Epworth Sleepiness Scale (ESS) score (Mean Difference (MD) −2.73, (95 % Confidence Interval (CI) [−3.25, −2.20], p &lt; 0.01) and Maintenance of Wakefulness Test (MWT) score (MD 6.00 (95 % CI [2.66, 9.33] p &lt; 0.01). Solriamfetol, followed by Pitolisant and modafinil, exhibited the greatest ESS reduction, while Danavorexton, followed by Solriamfetol and MK-7288, had the strongest impact on MWT. MK-7288 had the most total adverse events (AEs), followed by Danavorexton and armodafinil. Pharmacological Interventions significantly alleviate EDS in OSA patients but with heterogeneity across medications. Treatment decisions should involve a personalized assessment of patient factors and desired outcomes.</p></div>","PeriodicalId":49513,"journal":{"name":"Sleep Medicine Reviews","volume":"76 ","pages":"Article 101934"},"PeriodicalIF":11.2000,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluating pharmacological treatments for excessive daytime sleepiness in obstructive sleep apnea: A comprehensive network meta-analysis and systematic review\",\"authors\":\"Seyed Sina Neshat ,&nbsp;Afshin Heidari ,&nbsp;Mario Henriquez-Beltran ,&nbsp;Kripa Patel ,&nbsp;Brendon Colaco ,&nbsp;Vichaya Arunthari ,&nbsp;Alejandra Yu Lee Mateus ,&nbsp;Joseph Cheung ,&nbsp;Gonzalo Labarca\",\"doi\":\"10.1016/j.smrv.2024.101934\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Obstructive sleep apnea (OSA) is associated with excessive daytime sleepiness (EDS). Pharmacotherapy offers a potential treatment approach for EDS in OSA patients. This systematic review and meta-analysis aimed to assess the efficacy and safety of pharmacological interventions for alleviating EDS in patients with OSA. Following PRISMA guidelines, we included randomized controlled trials investigating pharmacological treatments for EDS in adult OSA until August 2023. We conducted meta-analysis, subgroup, and meta-regression analyses using a random effects model. Finally, a network meta-analysis synthesized direct and indirect evidence, followed by a comprehensive safety analysis. We included 32 articles in the meta-analysis (n = 3357). Pharmacotherapy showed a significant improvement in the Epworth Sleepiness Scale (ESS) score (Mean Difference (MD) −2.73, (95 % Confidence Interval (CI) [−3.25, −2.20], p &lt; 0.01) and Maintenance of Wakefulness Test (MWT) score (MD 6.00 (95 % CI [2.66, 9.33] p &lt; 0.01). Solriamfetol, followed by Pitolisant and modafinil, exhibited the greatest ESS reduction, while Danavorexton, followed by Solriamfetol and MK-7288, had the strongest impact on MWT. MK-7288 had the most total adverse events (AEs), followed by Danavorexton and armodafinil. Pharmacological Interventions significantly alleviate EDS in OSA patients but with heterogeneity across medications. Treatment decisions should involve a personalized assessment of patient factors and desired outcomes.</p></div>\",\"PeriodicalId\":49513,\"journal\":{\"name\":\"Sleep Medicine Reviews\",\"volume\":\"76 \",\"pages\":\"Article 101934\"},\"PeriodicalIF\":11.2000,\"publicationDate\":\"2024-04-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Sleep Medicine Reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1087079224000388\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sleep Medicine Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1087079224000388","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

阻塞性睡眠呼吸暂停(OSA)与白天过度嗜睡(EDS)有关。药物疗法是治疗 OSA 患者 EDS 的一种潜在方法。本系统综述和荟萃分析旨在评估药物干预对减轻 OSA 患者 EDS 的疗效和安全性。根据 PRISMA 指南,我们纳入了 2023 年 8 月之前调查成人 OSA EDS 药物治疗的随机对照试验。我们采用随机效应模型进行了荟萃分析、亚组分析和元回归分析。最后,网络荟萃分析综合了直接和间接证据,并进行了全面的安全性分析。我们在荟萃分析中纳入了 32 篇文章(n = 3357)。药物治疗可显著改善埃普沃思嗜睡量表(ESS)评分(平均差(MD)-2.73,(95 % 置信区间(CI)[-3.25,-2.20],p < 0.01)和保持清醒测试(MWT)评分(MD 6.00,(95 % CI [2.66,9.33] p < 0.01)。Solriamfetol 对ESS 的降低幅度最大,其次是 Pitolisant 和 modafinil,而 Danavorexton 对 MWT 的影响最大,其次是 Solriamfetol 和 MK-7288。MK-7288 的总不良事件(AEs)最多,其次是达那伐他汀和阿莫达非尼。药物干预能明显缓解 OSA 患者的 EDS,但不同药物之间存在差异。治疗决策应包括对患者因素和预期结果的个性化评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Evaluating pharmacological treatments for excessive daytime sleepiness in obstructive sleep apnea: A comprehensive network meta-analysis and systematic review

Obstructive sleep apnea (OSA) is associated with excessive daytime sleepiness (EDS). Pharmacotherapy offers a potential treatment approach for EDS in OSA patients. This systematic review and meta-analysis aimed to assess the efficacy and safety of pharmacological interventions for alleviating EDS in patients with OSA. Following PRISMA guidelines, we included randomized controlled trials investigating pharmacological treatments for EDS in adult OSA until August 2023. We conducted meta-analysis, subgroup, and meta-regression analyses using a random effects model. Finally, a network meta-analysis synthesized direct and indirect evidence, followed by a comprehensive safety analysis. We included 32 articles in the meta-analysis (n = 3357). Pharmacotherapy showed a significant improvement in the Epworth Sleepiness Scale (ESS) score (Mean Difference (MD) −2.73, (95 % Confidence Interval (CI) [−3.25, −2.20], p < 0.01) and Maintenance of Wakefulness Test (MWT) score (MD 6.00 (95 % CI [2.66, 9.33] p < 0.01). Solriamfetol, followed by Pitolisant and modafinil, exhibited the greatest ESS reduction, while Danavorexton, followed by Solriamfetol and MK-7288, had the strongest impact on MWT. MK-7288 had the most total adverse events (AEs), followed by Danavorexton and armodafinil. Pharmacological Interventions significantly alleviate EDS in OSA patients but with heterogeneity across medications. Treatment decisions should involve a personalized assessment of patient factors and desired outcomes.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Sleep Medicine Reviews
Sleep Medicine Reviews 医学-临床神经学
CiteScore
20.10
自引率
3.80%
发文量
107
期刊介绍: Sleep Medicine Reviews offers global coverage of sleep disorders, exploring their origins, diagnosis, treatment, and implications for related conditions at both individual and public health levels. Articles comprehensively review clinical information from peer-reviewed journals across various disciplines in sleep medicine, encompassing pulmonology, psychiatry, psychology, physiology, otolaryngology, pediatrics, geriatrics, cardiology, dentistry, nursing, neurology, and general medicine. The journal features narrative reviews, systematic reviews, and editorials addressing areas of controversy, debate, and future research within the field.
期刊最新文献
Editorial Board Proposing a definition for sleep disorders: An epistemological review Effectiveness of digital cognitive behavioral therapy for insomnia on professional activity: A systematic review and meta-analysis of randomized controlled trials Designing sleep disruption: The digital persuasion underlying screen use and sleep Reliability and validity of instruments containing reported sleep measures among children from birth to <5 years of age: A systematic review
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1